JP2025120179A5 - - Google Patents

Info

Publication number
JP2025120179A5
JP2025120179A5 JP2025077567A JP2025077567A JP2025120179A5 JP 2025120179 A5 JP2025120179 A5 JP 2025120179A5 JP 2025077567 A JP2025077567 A JP 2025077567A JP 2025077567 A JP2025077567 A JP 2025077567A JP 2025120179 A5 JP2025120179 A5 JP 2025120179A5
Authority
JP
Japan
Prior art keywords
antibody
immunoglobulin
heavy chain
region
regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025077567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025120179A (ja
Filing date
Publication date
Priority claimed from JP2021566278A external-priority patent/JP7760377B2/ja
Application filed filed Critical
Publication of JP2025120179A publication Critical patent/JP2025120179A/ja
Publication of JP2025120179A5 publication Critical patent/JP2025120179A5/ja
Pending legal-status Critical Current

Links

JP2025077567A 2019-05-09 2025-05-07 タンパク質を多量体化する変異体ドメイン及びその分離 Pending JP2025120179A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19173633 2019-05-09
EP19173633.9 2019-05-09
JP2021566278A JP7760377B2 (ja) 2019-05-09 2020-05-08 タンパク質を多量体化する変異体ドメイン及びその分離
PCT/NL2020/050298 WO2020226502A2 (en) 2019-05-09 2020-05-08 Variant domains for multimerizing proteins and separation thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021566278A Division JP7760377B2 (ja) 2019-05-09 2020-05-08 タンパク質を多量体化する変異体ドメイン及びその分離

Publications (2)

Publication Number Publication Date
JP2025120179A JP2025120179A (ja) 2025-08-15
JP2025120179A5 true JP2025120179A5 (cg-RX-API-DMAC7.html) 2026-02-12

Family

ID=66476558

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566278A Active JP7760377B2 (ja) 2019-05-09 2020-05-08 タンパク質を多量体化する変異体ドメイン及びその分離
JP2025077567A Pending JP2025120179A (ja) 2019-05-09 2025-05-07 タンパク質を多量体化する変異体ドメイン及びその分離

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021566278A Active JP7760377B2 (ja) 2019-05-09 2020-05-08 タンパク質を多量体化する変異体ドメイン及びその分離

Country Status (16)

Country Link
US (1) US20210054049A1 (cg-RX-API-DMAC7.html)
EP (1) EP3966238A2 (cg-RX-API-DMAC7.html)
JP (2) JP7760377B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220017909A (cg-RX-API-DMAC7.html)
CN (2) CN114702587A (cg-RX-API-DMAC7.html)
AR (1) AR118898A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020268684C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022405A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139402A1 (cg-RX-API-DMAC7.html)
IL (1) IL287928A (cg-RX-API-DMAC7.html)
MA (1) MA55884A (cg-RX-API-DMAC7.html)
MX (1) MX2021013646A (cg-RX-API-DMAC7.html)
PH (1) PH12021552833A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112399PA (cg-RX-API-DMAC7.html)
TW (1) TW202108613A (cg-RX-API-DMAC7.html)
WO (1) WO2020226502A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094318A1 (en) * 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
MX2023007028A (es) * 2020-12-18 2023-09-21 Kiniksa Pharmaceuticals Ltd Composiciones de proteínas y métodos para producir y usar las mismas.
MX2023015461A (es) * 2021-06-17 2024-01-18 Fapon Biotech Inc Inmunoglobulina quimerica.
CN121824747A (zh) 2022-12-27 2026-04-10 美勒斯公司 产生双重特异性蛋白的方法
TW202544033A (zh) 2024-04-15 2025-11-16 荷蘭商美勒斯公司 Cd3結合結構域
TW202608928A (zh) 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體藥物偶聯物
TW202608927A (zh) 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體-藥物偶聯物
WO2026013015A1 (en) 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026018064A1 (en) 2024-07-16 2026-01-22 Merus N.V. Multispecific multi-drug antibody-drug conjugates

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
EP1554392A4 (en) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv IDENTIFICATION OF NEW NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES WITH WIDE CROSS-REACTIVITY USING SEQUENTIAL ANTIGEN PANNING OF PHAG DISPLAY LIBRARIES
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
CA2595169A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
JP5144499B2 (ja) * 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-her 항체
TW201212938A (en) * 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
JP2014511836A (ja) * 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ, エセ.アー. ヘテロ二量体免疫グロブリン
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
DK2766392T3 (da) * 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
BR112014010257A2 (pt) * 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
WO2013157953A1 (en) * 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN104045714B (zh) * 2013-03-14 2019-01-11 南京金斯瑞生物科技有限公司 曲妥珠单抗突变体IgG及其应用
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
EP3174897B1 (en) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
MA41375A (fr) * 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
SG11201810470XA (en) * 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins
WO2017218698A1 (en) * 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
KR20200037250A (ko) 2017-07-06 2020-04-08 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 항체
TWI917306B (zh) 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
TWI887193B (zh) 2017-07-06 2025-06-21 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CA3094318A1 (en) 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
CN110272495A (zh) * 2019-06-11 2019-09-24 南京华岩生物技术有限公司 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Similar Documents

Publication Publication Date Title
Franklin STRUCTURAL STUDIES OF HUMAN 7S γ-GLOBULIN (G IMMUNOGLOBULIN) Further Observations of a Naturally Occurring Protein Related to the Crystallizable (Fast) Fragment
TWI596107B (zh) 單株抗體之新穎純化方法
TWI913830B (zh) 微晶片毛細管電泳分析及試劑
JP2025109759A5 (cg-RX-API-DMAC7.html)
RU2580020C2 (ru) Способ снижения гетерогенности антител и способ получения соответствующих антител
JPH09506001A (ja) 異種二重特異性抗体の製造法
EP3966238A2 (en) Variant domains for multimerizing proteins and separation thereof
JP7817743B2 (ja) タンパク質の精製の改善されたプロセス
US20200377560A1 (en) Antibodies to royalactin and uses thereof
US20230049176A1 (en) Methods to decrease impurities from recombinant protein manufacturing processes
TWI872049B (zh) 生成包含有兩種或更多種抗體的組成物之技術
NZ782091B2 (en) Variant domains for multimerizing proteins and separation thereof
Gugerli et al. Etiological studies and diagnosis of grapevine leafroll disease improved by monoclonal antibodies
US20260117000A1 (en) Process of purification of protein
US10308716B2 (en) Method for producing polyclonal antibodies using an antigenic composition comprising protein-containing membrane vesicles
US20260116917A1 (en) Process of purification of protein
JP2004081042A (ja) タンパク質溶液の調製方法、当該タンパク質溶液、当該タンパク質溶液を利用したモノクローナル抗体の作製方法及び当該モノクローナル抗体
JP3858945B2 (ja) ハイブリドーマの選抜方法
JP2024521871A (ja) マイクロチップキャピラリー電気泳動アッセイ及び試薬
CN114409798A (zh) 制备包含两种或更多种抗体的组合物
TW202445126A (zh) 基於質譜法之體內共表現抗體之表徵
CN113439090A (zh) 制备包含两种或更多种抗体的组合物
KR20250025373A (ko) 하류 항체 정제에서 uf/df 풀로부터의 집합체의 클리어런스
CN120775035A (zh) 特异性单克隆抗体及其在猴痘病毒检测、中和的应用
RU2024139941A (ru) Способы очистки полиспецифических антител